STATEN
ISLAND, N.Y., Jan. 3, 2024
/PRNewswire/ -- Acurx Pharmaceuticals, Inc.
(NASDAQ: ACXP) ("Acurx" or the "Company")
today announced that President and Chief Executive Officer
David P. Luci will present at the
42nd Annual J.P. Morgan Healthcare Conference on
Thursday, January 11, 2024 at
12:00 pm PST. An audio webcast of the
presentation will be available live at
https://jpmorgan.metameetings.net/events/healthcare24/sessions/50099-acurx-pharmaceuticals-inc/webcast?gpu_only=true&kiosk=true
and will be available upon completion of the conference on the
Company's website at www.acurxpharma.com under the Investors
section.
About Acurx Pharmaceuticals, Inc.
Acurx
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on developing new antibiotics for difficult to treat
infections. The Company's approach is to develop antibiotic
candidates with a Gram-positive selective spectrum (GPSS®) that
blocks the active site of the Gram+ specific bacterial enzyme DNA
polymerase IIIC (pol IIIC), inhibiting DNA replication and leading
to Gram-positive bacterial cell death. Its R&D pipeline
includes antibiotic product candidates that target Gram-positive
bacteria, including Clostridioides difficile, methicillin-resistant
Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus
(VRE) and drug-resistant Streptococcus pneumoniae (DRSP).
To learn more about Acurx
Pharmaceuticals and its product pipeline, please visit
www.acurxpharma.com
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci
President & CEO
Tel: 917-533 1469
Email: davidluci@acurxpharma.com
View original
content:https://www.prnewswire.com/news-releases/acurx-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302024975.html
SOURCE Acurx Pharmaceuticals, Inc.